Baricitinib Versus Dexamethasone for Adults Hospitalized with COVID-19

Decorative image of the COVID-19 Learning Lounge

Baricitinib Versus Dexamethasone for Adults Hospitalized with COVID-19

SUMMARY

In hospitalized patients with COVID-19 requiring supplemental oxygen, a combination of baricitinib, dexamethasone, and remdesivir resulted in similar survival rates by day 29 compared to the control. However, dexamethasone was associated with significantly more treatment-related adverse events and severe or life-threatening adverse events. bioMérieux Antimicrobial Stewardship Director Katherine Perez, PharmD, participated in this study with the National Institute of Allergy and Infectious Diseases (NIAID).

FEATURED EXPERT

Katherine Perez, PharmD, Antimicrobial Stewardship Director at bioMérieux

GET STARTED

Read the article at the Lancet.

Take me there now!

Read time: 45 minutes

We want to hear from you!

Your feedback helps us continue to provide resources and content specific to your needs.

Take Our Poll

Global Solutions

BIOMÉRIEUX EPISEQ^®

Provides easy-to-use applications for clinical microbiologists: clinical pathogen outbreak management, microbiome profiling, and SARS-CoV-2 genomics variants identification.

Learn More

US Solutions

BIOFIRE^® FILMARRAY^®

The FILMARRAY is an FDA-cleared multiplex PCR system that integrates sample preparation, amplification, detection and analysis. It requires just a few minutes of hands-on-time and its turnaround time is just about an hour, giving you faster results which may lead to better patient care.

Learn More

PUBLISHED BY

The Lancet
May 23, 2022